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needle biopsies can sometimes provide such 
a sample, but if EBUS ‑TBNA is not conclusive, 
mediastinoscopy is still a confirmatory test.6
The aim of this study was to evaluate efficacy 
of EBUS/EUS ‑b‑NA using histological 25G core 
needles in a detailed diagnosis of patients with 
advanced LC.
Patients and methods A single ‑center prospec‑
tive observational study was conducted in John 
Paul II Hospital in Kraków, Poland. Consecutive 
patients with confirmed or suspected advanced 
LC were included. Since the procedure is routine‑
ly used, the approval of bioethics committee was 
not required.
After the  informed consent was obtained, 
the EBUS/EUS ‑b‑NA procedure was performed 
under mild conscious sedation with intravenous 
midazolam (2–5 mg) and fentanyl (0.025–0.1 mg). 
Flexible videobronchoscopes with a integrated 
convex ultrasound probe (BF ‑UC180F, Olympus 
Medical Systems Corporation, Tokyo, Japan), 
which can visualize mediastinal and hilar struc‑
tures, were used for all procedures. The biopsies 
were performed with 25G core needles (Echo‑
Tip ProCore Endobronchial HD Biopsy Needle, 
Cook Endoscopy Inc., Limeric, Ireland) with 2 to 
5 needle passes in at least 2 selected areas. Both 
the smears and the cell blocks were prepared from 
obtained samples.
If the biopsy specimen was positive for LC, 
it was sent to perform IHC tests: thyroid tran‑
scription factor 1 (TTF‑1), p40, CD56, Ki67. 
If non–small cell lung cancer was diagnosed, 
the specimen was sent to run molecular test‑
ing for mutations of epidermal growth factor re‑
ceptor, translocations of anaplastic lymphoma 
Introduction Lung cancer (LC) remains the most 
common cause of cancer ‑related mortality world‑
wide. Despite the efforts made to detect it early, 
only 15% to 20% of newly diagnosed LC patients 
are in early stages at the time of the diagnosis 
and are eligible for surgical treatment. A target‑
ed oncological treatment should be considered in 
the majority of patients with advanced LC (stage 
IIIB and IV). It is important to obtain from the le‑
sions adequate cytological or histological samples 
that are suitable for immunohistochemistry (IHC) 
and broader molecular testing (MT).1
A combination of positron emission tomog‑
raphy with computed tomography and minimal‑
ly invasive procedures including endobronchial 
ultrasound ‑guided transbronchial needle aspi‑
ration (EBUS ‑TBNA) and endoscopic ultrasound‑
‑guided fine‑needle aspiration (EUS ‑b‑FNA) 
with single EBUS scope is a standard procedure 
in LC staging.2 Recent guidelines on the tech‑
nical aspects of EBUS ‑TBNA recommend using 
a 22 ‑gauge (G) or 21G cytological needle.3
For decades, transthoracic and transabdominal 
core needle biopsies have been the standard pro‑
cedures for the diagnostic workup of malignan‑
cies.4 Both thicker cytological 19G needles and 
core histological 22G / 25G needles proved to be 
useful in performing core EUS ‑guided biopsies in 
gastroenterology5 (see also references 1 and 2 in 
Supplementary material). Thereafter, histologi‑
cal core needles started to be used endobronchi‑
ally, but their efficacy to obtain sufficient mate‑
rial for IHC and MT in the diagnostic workup of 
patients with LC is still unknown.
In some cases, it is crucial to assess the his‑
tological structure of the lesion to diagnose and 
treat the patient correctly (eg, lymphoma). Core 
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with the standard 22G needle. A maximum exten‑
sion of this needle is 5 cm.8 Nevertheless, the lit‑
erature describing usefulness of this needle in ob‑
taining material suitable for IHC and MT is scarce.
Our study showed that 25G ProCore needles 
can be successfully used for this purpose. Those 
results must be considered as preliminary and re‑
quiring further investigation, because our study 
had its limitations, namely, a small group of pa‑
tients and a noncomparative protocol.
Also considering statistical analysis, both ac‑
curacy and PPV are influenced by a selection bias, 
so their value is limited.
There is only one retrospective review com‑
paring core biopsy needles (EchoTip 22/25G Pro‑
Core) with standard ones (SonoTip II 22G) in 
which a yield obtained by the first one was im‑
proved comparing with the standard one in test‑
ing for malignancy.9 On the other hand, more re‑
cent data do not show significant difference be‑
tween 22G and 25G cytological needles regard‑
ing specimen adequacy for histology and molec‑
ular testing.10,11
Also, the comparison between 22G and 25G 
ProCore needles for mediastinal and hilar lymph‑
adenopathy presented by Yang et al12 did not show 
significant difference in the diagnostic yield.
As the core needles are significantly more ex‑
pensive, and their diagnostic yield seems to be 
of no advantage comparing with standard ones, 
it is necessary to identify the precise indications 
for the use of 25G ProCore in clinical practice. 
The data from the literature is very limited (see 
references 3 and 4 in Supplementary material). 
However, both conclusions drawn by other au‑
thors and our experience point to improvement 
of flexibility of EBUS scope loaded with a 25G 
needle, which is important in puncturing both 
the upper paratracheal region and peripheral hi‑
lar lesions / lymph nodes (eg, level 12L in the left 
upper lobe). The other important indication for 
a 25G needle could be the need to obtain a biop‑
sy specimen from a lesion located behind a ves‑
sel (transvascular biopsy) or hypervascular tumor 
(ie, metastatic renal cell carcinoma).
Both flexibility and sharpness of 25G needles 
that allow for more precise puncturing of small 
or fibrotic (after induction therapy) lymph nodes 
make them useful also in LC (re)staging. But it 
is under debate whether the more expensive 25G 
ProCore histological needles have any advantage 
over 25G cytological ones in this indication.
In conclusion, the endosonography with his‑
tological 25G core needles is feasible and safe, so 
it seems to be a reasonable approach in select‑
ed clinical situations for IHC and MT in patients 
with advanced LC.
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Supplementary material is available with the article at www.mp.pl/paim.
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kinase, and expression of programmed death 
ligand 1.
If the biopsy result was negative or inconclu‑
sive, it was repeated with standard 22G cytolog‑
ical needles as the confirmatory test.
Results From January 2019 to April 2019, 20 
patients (13 men [65%] and 7 women [35%]) at 
a mean (SD) age 68 (6.4) years underwent en‑
dosonography. Histological examination was 
conclusive in 18 patients: small cell lung can‑
cer (8 patients), adenocarcinoma (6 patients), 
squamous cell carcinoma (3 patients), and not 
otherwise specified (1 patient). Sensitivity, ac‑
curacy, and positive predictive value (PPV) for 
the histology and IHC tests in the whole group 
were 90%, 90%, 100%, respectively. In 2 samples 
with false ‑negative results, in which some undif‑
ferentiated cancer cells were only found, EBUS‑
‑TBNA with a 22G needle confirmed small cell 
lung cancer (1 patient) and squamous cell carci‑
noma (1 patient).
The mean (range) size of biopsied lymph nodes 
was 30.25 mm (17–70 mm). EBUS ‑TBNA was per‑
formed in 10 patients with LC, and EUS ‑b‑FNA 
in 7, as a single procedure. Combined procedure 
EBUS/EUS ‑b‑NA was used in the next 3 cases. 
The nodal station 7 was biopsied in 13 patients. 
Stations 4R, 11L, 4L, 10R, 2R, and 8 were biop‑
sied in 8, 5, 4, 3, 2, and 2 patients, respective‑
ly. On average, 2 different nodal stations per pa‑
tient were biopsied.
In 8 of 11 patients with non –small cell lung 
cancer sensitivity, accuracy, and PPV for endo‑
sonography with 25G core needles for MT were 
72.7%, 72.7%, 100%, respectively. No complica‑
tions after all biopsies were observed.
Discussion Endosonography with 25G core nee‑
dles in our prospective observational study had 
high diagnostic yield for histology, IHC, and MT 
and good safety profile in patients with advanced 
LC.
At present, there is a variety of cytological nee‑
dles available for biopsy: thicker 19G, standard 
21G and 22G, and thinner 25G.7
The EchoTip 25G ProCore needle was designed 
to provide a histological biopsy material, because 
it is equipped with a core trap close to its tip 
(fIguRE 1). It is also 33% more flexible compared 




needle aspiration of 
the mediastinal mass; 
white arrow points to 
a window in the needle’s 
tip.
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